

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 8,569 -- ACTH<sub>4-10</sub> (OI-63)

Dear Sir:

The sponsorship of IND 8,569 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 12,238 — GC-46

Dear Sir:

The sponsorship of IND 12,238 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 12,987 -- ACTH<sub>4-9</sub> (ORG 2766)

Dear Sir:

The sponsorship of IND 12,987 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 13,059 -- ORG 2566

Dear Sir:

The sponsorship of IND 13,059 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 13,060 — ORG 2313

Dear Sir:

The sponsorship of IND 13,060 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 14,915 — ORG 3770 (6-azamianserin)

Dear Sir:

The sponsorship of IND 14,915 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 14,963 — ORG 2305

Dear Sir:

The sponsorship of IND 14,963 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 16,111 — GK-78

Dear Sir:

The sponsorship of IND 16,111 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 16,195 -- ORG 2408

Dear Sir:

The sponsorship of IND 16,195 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 16,905 -- ORG 6582

Dear Sir:

The sponsorship of IND 16,905 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 16,906 -- DGAVP

Dear Sir:

The sponsorship of IND 16,906 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry

**Stony Brook**

Department of Psychiatry and Behavioral Science  
State University of New York at Stony Brook  
Stony Brook, NY 11794  
telephone: (516) 246-2413

October 18, 1982

Paul Leber, M.D.  
Division of Neuropharmacological Products  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857


Ref: IND 17,365 - Mianserin

Dear Sir:

The sponsorship of IND 17,365 is transferred to the Pharmaceutical Research Institute of Worthington, Ohio, effective this date.

Other investigators studying this compound under this IND are being informed of this transfer.

Sincerely yours,



Max Fink, M.D.  
Professor of Psychiatry